Shares of Milestone Pharmaceuticals plunged 15.7% to $1.07 in pre-market trading on August 12, moments before the company is set to release second-quarter results and host an investor call at 8:30 a.m. ET. With broader indexes trading modestly higher , the selloff is squarely company-specific, suggesting investors are bracing for disappointing numbers from a firm whose only product — a self-administered nasal spray for sudden rapid heartbeat episodes — is barely off the launch pad.
A Drug Launch Still Measured in Thousands, Not Millions. Milestone generated just $0.2 million in product revenue in Q1 2026 from its first quarter of commercial sales , against analyst expectations of roughly $0.8 million for Q2. The drug is expected to be used only 3–5 times per year per patient , meaning per-patient revenue accumulates slowly. Through April, the company counted about 600 prescriptions from roughly 400 unique prescribers — encouraging breadth, but tiny volume for a company burning tens of millions quarterly.
The Cash Runway Is Shrinking Fast. Milestone's net loss widened to $26.1 million in Q1, up from $20.8 million a year earlier, driven mainly by higher commercial spending . Commercial expenses hit $15.8 million in Q1 alone, up from $10.4 million . The company held $184.2 million in cash and short-term investments at quarter's end , enough to fund operations into late 2027. But the math is unforgiving at a $26 million quarterly burn rate — every quarter of slow prescription growth eats directly into that cushion.
Dilution Risk Looms Large. Milestone filed a shelf registration to offer up to $300 million in securities, including a $100 million at-the-market equity sales agreement with Cantor Fitzgerald . Shareholders have already been diluted by 46% over the past year . With the stock near its 52-week low of $1.00, any further share issuance would be deeply punitive.
Shorts Are Circling. Short interest stands at 20.8% — a bet by bears that the launch trajectory won't justify the spending. Analysts' average price target remains $6.33 , but that assumes a commercial ramp that hasn't materialized yet. Today's report will either validate that optimism with accelerating prescription counts and insurance wins — or confirm the fear that Milestone is spending $100 million a year to sell a product that may take far longer than expected to find its audience.